Forbes J M & CO LLP Nuvectis Pharma, Inc. Transaction History
Forbes J M & CO LLP
- $905 Million
- Q1 2024
A detailed history of Forbes J M & CO LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Forbes J M & CO LLP holds 34,000 shares of NVCT stock, worth $213,520. This represents 0.03% of its overall portfolio holdings.
Number of Shares
34,000
Previous 34,000
-0.0%
Holding current value
$213,520
Previous $283,000
1.77%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding NVCT
# of Institutions
38Shares Held
2.11MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$3.53 Million5.37% of portfolio
-
Black Rock Inc. New York, NY373KShares$2.34 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA299KShares$1.88 Million0.0% of portfolio
-
Baldwin Brothers LLC154KShares$967,9360.1% of portfolio
-
Geode Capital Management, LLC Boston, MA135KShares$844,8350.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $92M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...